NovaBay Pharma (NBY) Misses Q4 EPS by 2c

NovaBay Pharma (NYSE: NBY) reported Q4 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $385 thousand versus the consensus estimate of $60 thousand.

For earnings history and earnings-related data on NovaBay Pharma (NBY) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• BMO starts chip stocks coverage: Here are its preferred picks
• Is the global equity rally broadening? UBS weighs in